Chiusura precedente | 9,91 |
Aperto | 9,95 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 9,65 - 10,08 |
Intervallo di 52 settimane | 7,26 - 29,70 |
Volume | |
Media Volume | 778.499 |
Capitalizzazione | 1,14B |
Beta (5 anni mensile) | 0,93 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,71 |
Prossima data utili | 10 nov 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 14,46 |
Saint-Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has initiated rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s single-shot chikungunya vaccine candidate in persons aged 18 years and above. This BLA submission follows final pivotal Phase 3 data reported in March 20221 and final lot-to-lot consistency results r
Saint Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has decided not to exercise the second option year of the contract1 to supply Valneva’s Japanese encephalitis (JE) vaccine IXIARO®. Due to the past and ongoing impact of the COVID-19 pandemic on its operations, the DoD considers its existing IXIARO® supply levels sufficient to meet current needs. The DoD has communicated
Saint-Herblain (France), August 15, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an At-the-Market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0 million of American Depositar